- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Mantle cell lymphoma
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Acalabrutinib – July 2025
Acalabrutinib; Tablet 100 mg; Calquence®
Last updated
9 July 2025